Pulse Explorar nav.journalClub Debates Tendencias Investigadores

Join discussions, follow papers, and never miss your next session.

Download on theApp Store

Inicio Explorar nav.journalClub Tendencias

⌘+K

An Overview of Targeted Alpha Therapy with 225Actinium and 213Bismuth | Synapse

September 11, 2018

Ver artículo completo

An Overview of Targeted Alpha Therapy with 225Actinium and 213Bismuth

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

Background: Recent reports of the remarkable therapeutic efficacy of 225Ac-labeled PSMA- 617 for therapy of metastatic castration-resistant prostate cancer have underlined the clinical potential of targeted alpha therapy. Objective and Conclusion: This review describes methods for the production of 225Ac and its daughter nuclide 213Bi and summarizes the current clinical experience with both alpha emitters with particular focus on recent studies of targeted alpha therapy of bladder cancer, brain tumors, neuroendocrine tumors and prostate cancer.

Preguntar a la IA

Me gusta

Guardar

Compartir

Ver artículo completo

Preguntar a la IA

Me gusta

Guardar

Compartir

Ver artículo completo

Cite This Study

Morgenstern et al. (Tue,) studied this question.

synapsesocial.com/papers/6a013ade6018b8d0892dede8 https://doi.org/https://doi.org/10.2174/1874471011666180502104524